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ARTICLE
AbstrAct
Intravenous tranexamic acid (TXA) has been identified to be effective in total knee arthroplasty (TKA), but the effect of topical application is still unclear. Therefore, the authors conducted a meta-analysis to assess the effect of topical TXA in TKA. Twelve trials with a total of 1179 knees were included. The results revealed that the application of topical TXA in TKA significantly reduced total blood loss by a mean of 280.65 mL and reduced transfusions without increasing the risks of deep venous thrombosis and pulmonary embolism. Topical TXA also reduced postoperative drain output by a mean of 194.59 mL and lowered postoperative hemoglobin drop by a mean of 0.66 g/dL. In addi-
Effect of Topical Tranexamic Acid in Reducing Bleeding and Transfusions in TKA
tion, subgroup analysis showed that highconcentration TXA may be better at reducing bleeding and transfusions than lowconcentration TXA. Therefore, the authors concluded that topical TXA can effectively reduce bleeding and transfusion rate in TKA without increasing the risk of deep venous thrombosis and pulmonary embolism, and high-concentration (20 mg/ mL or more) topical TXA is recommended. T otal knee arthroplasty (TKA) is routinely used to treat end-stage osteoarthritis and other joint diseases, such as rheumatoid arthritis. The final result of TKA is satisfactory in most patients. However, TKA is associated with significant blood loss, 1,2 often requiring allogenic blood transfusions. A transfusion rate of 11% to 21% has been reported in TKA. 3 However, transfusion may carry potential risks, such as immunological reactions, infection, intravascular hemolysis, renal failure, and even death, and it should be avoided if possible. 4, 5 Numerous methods of controlling bleeding have been used to avoid transfusion, including autologous blood transfusion, intraoperative blood saving, hypotensive anesthesia, erythropoietin, and the use of antifibrinolytic agents. 6, 7 Tranexamic acid (TXA), a kind of synthetic antifibrinolytic, can inhibit both fibrinolysis and the activation of plasminogen by plasminogen activator; therefore, it is able to delay fibrinolysis and stop bleeding. 8 Tranexamic acid has been used successfully in dental extraction, tonsillectomy, prostate surgery, heavy menstrual bleeding, and cardiac surgery and in patients with hemophilia. 7 Benoni et al 9 first reported the efficacy of TXA in TKA in 1994, and numerous studies have explored the efficacy and safety of intravenous (IV) TXA in reducing blood loss and transfusions. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Almost all of these studies reached the positive conclusion that IV TXA may reduce bleeding and transfusion rate without increasing the risk of deep venous thrombosis (DVT) in TKA.
Compared with IV TXA, topical TXA has the advantages of being easy to administer, providing a maximum concentration of TXA at the bleeding site, and being associated with little or no systemic TXA absorption. 20 Wong et al 21 reported that topical application of TXA directly into the surgical wound reduced postoperative bleeding by 300 to 400 mL, resulting in 16% to 17% higher postoperative hemoglobin levels compared with placebo. Alshryda et al 20 reported that topical TXA was effective in reducing the need for blood transfusion after TKA without adverse effects. However, some studies had the shortcomings of poor design, small sample size, low power, and inconclusive results, so the results may have prejudiced the use of these potentially valuable agents. In addition, although 2 related systematic reviews assessed the effect of topical TXA in TKA and reached the same positive conclusion, 22, 23 the quantity of literature included in the reviews was insufficient, so their conclusions may be biased. Therefore, the current authors performed a systematic review and metaanalysis to investigate the efficacy and safety of topical TXA for reducing bleeding and transfusions in TKA.
MAteriAls And Methods
Search Strategy
Two reviewers (C.Y., P.K.) independently completed a systematic literature review of electronic databases, including Ovid, PubMed, EMBASE, ScienceDirect, and CNKI, for all articles about TXA application in TKA published in English and Chinese from 1980 to January 2014. In addition, the reference lists of the retrieved articles were manually checked for additional studies that met the inclusion criteria, but none were found. The keywords used for searching included tranexamic acid, TXA, total knee replacement, total knee arthroplasty, TKA, TKR, topical, and intraarticular. These keywords were collected using the Boolean operators "AND" and "OR."
Selection Criteria and Data Extraction
Two researchers (C.Y., P.K.) independently reviewed the titles and abstracts of all articles and excluded those that did not meet the inclusion criteria. The remaining articles were analyzed by reading the full texts carefully. Any disagreement regarding the search was resolved by discussion, with arbitration by a third author (F.P.) when differences remained. The inclusion criteria were randomized, controlled trials exploring the effect of topical TXA in TKA. The exclusion criteria were (1) studies on oral or intravenous TXA; (2) studies with no control group; (3) animal studies; and (4) studies with a sample size smaller than 40. The data were extracted independently by 2 researchers (C.Y., P.K.). The data recorded included authors' names, publication year, sample size, dose of topical TXA, concentration of topical TXA, intervention method, drainage time, blood transfusion protocol, DVT prophylaxis, and Jadad score. 24 The primary outcomes were total blood loss, transfusion rate, and DVT and pulmonary embolism (PE) events; the secondary outcomes were total drain output and postoperative hemoglobin drop.
Quality Assessment of the Included Literature
The Jadad score 24 was used to assess the methodological strength of the included literature, and the authors considered a Jadad score of more than 3 points to indicate high quality. Two authors (C.Y., P.K.) completed the assessments independently, and there were no differing views. The Jadad scale criteria are listed in Table 1 .
Statistical Analysis
The included studies were analyzed with RevMan 5.2 statistical software (Cochrane Collaboration, London, United Kingdom). Continuous data (total blood loss, total drain output, and postoperative hemoglobin drop) were recorded as weighted mean differences and 95% confidence intervals (CIs). Dichotomous data (transfusion rate and DVT and PE events) were recorded as proportions, and the effect of intervention was recorded as a risk ratio. 
Subgroup Analysis
The authors also evaluated the influence of different topical application doses and concentrations. For different doses, 2 subgroups were created: the low-dose topical TXA group included studies in which the total dose of topical TXA did not achieve 2 g, and the high-dose topical TXA group included studies in which the total dose of topical TXA was not less than 2 g. Similarly, for different concentrations, 2 subgroups were created: the low-concentration topical TXA group included studies in which the concentration of topical TXA was less than 20 mg/mL, and the high-concentration topical TXA group included studies in which the concentration of topical TXA was 20 mg/mL or more.
Subgroup analyses of different dose groups and concentration groups were performed for all the primary outcomes except PE.
results
Online Search
A total of 613 studies were identified after a search of Ovid, PubMed, EMBASE, the Cochrane Library, and CNKI and of the references of the retrieved articles. Duplicate studies were removed, leaving 47 studies. After reading the abstracts, 31 studies were excluded for being retrospective, for examining oral or IV TXA application, or for other reasons. The remaining 16 studies were assessed by reading the full texts, and 4 were excluded for poor design or too-small sample sizes. Finally, 12 studies 20, 21, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] involving 1179 knees met the inclusion criteria and were included in the cme ARTICLE meta-analysis. The details of study identification and inclusion and exclusion criteria are listed in Figure 1 .
Description of Included Studies
All included studies were published in English; no Chinese studies met the inclusion criteria. Most of the studies included small samples, but the studies had high Jadad scores. Of the 12 included studies, 3 received a Jadad score of 5, 20,21,28 4 received a Jadad score of 4, 25, 26, 29, 33 and 4 received a Jadad score of 3 [30] [31] [32] 34 ; these 11 studies were considered high quality. One study received a Jadad score of 2 points 27 ; however, its sample size was larger than those in the other studies, so it was included in the metaanalysis.
The most common diagnosis was osteoarthritis. Different doses and modes of TXA were used in different studies. The highest dose for topical application of TXA was 3 g, which was reported in 3 studies 21, 27, 31 ; the lowest dose was 0.25 g, which was reported in 2 studies. 25, 33 The concentrations of topical TXA ranged from a low of 10 mg/mL 25, 33 to a high of 100 mg/mL. 29, 30 Temporary postoperative clamping ranging from 30 minutes to 2 hours was reported in 8 studies 20, 25, 27, [29] [30] [31] [32] [33] ; Wong et al 21 and Martin et al 26 did not report the use of drainage. Ten studies 20, 21, [25] [26] [27] [28] [29] 31, 33, 34 described the blood transfusion protocol. In addition, 7 studies 20,21,26,28-31 gave detailed descriptions of the methods of prophylaxis against DVT; low-molecular-weight heparin (LMWH) or LMWH combined with mechanical prophylaxis were the most common methods, used in all studies except those of Ishida et al 30 and Martin et al. 26 The included studies are described in Table 2 .
Effect of Intervention
Primary Outcomes. Total Blood Loss. Eight studies examining 880 patients, including 513 patients in the TXA group and 367 patients in the control group, reported total blood loss. The use of topical TXA significantly reduced total blood loss by a mean of 280.65 mL (95% CI, -376.43 to -184.88; P<.00001). However, there was significant heterogeneity among the studies (I 2 =90%), so a random-effects model was used (Figure 2) .
Transfusion Rate. Transfusion rate was reported in 11 studies examining 1129 knees (652 in the TXA group and 477 in the control group). The current metaanalysis indicated a significantly lower risk of transfusion requirements in the TXA group compared with the control group (risk ratio=0.26; 95% CI, 0.19 to 0.37; P<.00001; I 2 =34%; fixed-effects model) (Figure 3 ). (Figures 4-5) .
Secondary Outcomes. Total Drain Output. Total drain output was reported in 5 studies examining 470 knees (258 in the TXA group and 212 in the control group). Total drain output in the TXA group was significantly less than that in the control group. Topical TXA effectively decreased drainage by a mean of 194.59 mL (95% CI, -315.86 to -73.32; P<.002). However, there was significant heterogeneity among the included studies (I 2 =63%), so a random-effects model was used (Figure 6) .
Postoperative Hemoglobin Drop. Postoperative hemoglobin drop was reported in 7 studies with 693 knees (419 in the TXA group and 274 in the control group). The use of TXA significantly reduced postoperative hemoglobin drop by a mean of 0.66 g/dL (95% CI, -0.81 to -0.52; P<.00001; I 2 =41%) (Figure 7) . Subgroup Analysis Outcomes. Different Dosage Groups. Using a forest plot of subgroup analysis for different doses, both high-dose and low-dose topical TXA significantly reduced total blood loss and transfusions without increasing the risk of DVT. However, the differences in total blood loss and transfusion between study groups were not significant (total blood loss: mean reduction of 294.43 mL in high-dose group vs 277.41 mL in low-dose group; transfusion rate: risk ratio=0.25 in high-dose group vs 0.26 in low-dose group) (Figure 8) .
Different Concentration Groups. Subgroup analysis of different concentrations presented a different result. Both highconcentration and low-concentration topical TXA significantly reduced total blood loss and transfusions without increasing the risk of DVT. However, there were significant differences in total blood loss and transfusions between different concentration groups (total blood loss: mean reduction of 335.79 mL in high-concentration group vs 213.47 mL in low-concentration group; transfusion rate: risk ratio=0.23 in high-concentration group vs 0.37 in lowconcentration group) (Figure 9 ).
discussion
The result of this meta-analysis showed that the topical application of TXA can effectively reduce total blood loss and transfusion rate without increasing the risk of DVT and PE in TKA. In addition, topical TXA can reduce total The reductions in total blood loss and transfusions and the safety of topical TXA, namely not increasing the risk of DVT and PE events, were its most important effects; therefore, the authors chose total blood loss, transfusion rate, and DVT and PE events as the primary outcomes.
A total of 12 studies examining 1179 knees were analyzed in this metaanalysis. The results revealed that the application of topical TXA significantly reduced total blood loss by a mean of 280. 23 showed different effects of high-dose and low-dose topical TXA. However, the number of studies they included was not high enough; therefore, to verify this conclusion, the current authors also performed subgroup analysis. In addition, previous studies reported that a topical TXA solution of 10 to 20 mg/mL was the lowest appropriate concentration for antifibrinolytic action, 23, 35, 36 and the effect of different concentrations of topical TXA for reducing bleeding and transfusions may be not the same, so the current authors also performed subgroup analysis on different concentrations. The results of subgroup analysis showed that bleeding and transfusion rates were related to the concentration of topical TXA rather than to the total dosage of topical TXA. The heterogeneity of total blood loss was very high, so the authors used a random-effects model to analyze these data, which may result in bias. The authors thought that several things may have resulted in the high heterogeneity, such as different drug dosages, different methods of anticoagulation, and different calculation methods. They felt that the most important reason for the high heterogeneity was that the calculation methods for total blood loss differed in different studies. Onodera et al 32 and Seo et al 34 did not report the calculation method used for total blood loss. Alshryda et al 20 used the Gross formula 37 to calculate total blood loss. Konig et al, 27 Georgiadis et al, 28 and Rajesh et al 31 used the formulas of Nadler et al 38 and Good et al 10 to evaluate total blood loss; Sa-ngasoongsong et al 33 reported that they used a specific formula 39,40 but did not give a detailed description. These different methods may carry bias and increase heterogeneity. For postoperative drain output, the heterogeneity was very high (I 2 =90%), and this may be caused by the different timing of drain clamping, drug dosages, and perioperative management protocols. The authors used a random-effects model to assess this, which may carry bias.
This meta-analysis has several strengths. First, compared with a related systematic review 22 and a previously published meta-analysis, 23 the current meta-analysis included more studies reported in the past year, so the results and conclusions may be more reliable. Second, the quality assessment scores for almost all of the included studies were high, which contributed to the strength of their conclusions. Third, through the subgroup analysis, the authors found that a high concentration of topical TXA can reduce bleeding and transfusions more effectively than a low concentration. However, high-dose TXA may not be more effective than low-dose TXA, a result that has not been previously reported. The main limitation of this metaanalysis was the high heterogeneity of total blood loss. The authors analyzed these data with a random-effects model, which may increase bias for the result. However, the authors did not feel that it would significantly influence the conclusion.
conclusion
Through this meta-analysis, the authors proved that (1) topical TXA can effectively reduce bleeding and transfusions in TKA without increasing the risk of DVT and PE and can also reduce postoperative drain output and hemoglobin drop; (2) both high-dose (≥2 g) and lowdose (<2 g) topical TXA can significantly reduce bleeding and transfusions, but a high dose may not be more effective in reducing bleeding and transfusions than a low dose; (3) high-concentration (≥20 mg/mL) topical TXA may be better at reducing bleeding and transfusions than low-concentration (<20 mg/mL) topical TXA.
references
